Diabetes Care · 2015 · 83 citations · 24 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDiabetologyNoncompartmental AnalysisDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlycemic ControlInsulin TherapyBasal Insulin TherapyBasal RegimensCombination Therapy With InsulinGlycemic Control TargetsGlycemic TargetsOral Antidiabetic MedicationsOral Hypoglycemic TherapyTreat-to-target Therapy
OBJECTIVE: To evaluate the efficacy and safety of basal insulin peglispro (BIL) versus insulin glargine in patients with type 2 diabetes (hemoglobin A1c [HbA1c] ≤9% [75 mmol/mol]) treated with basal insulin alone or with three or fewer oral antihyperglycemic medications. RESEARCH DESIGN AND METHODS: This 52-week, open-label, treat-to-target study randomized patients (mean HbA1c 7.42% [57.6 mmol/mol]) to BIL (n = 307) or glargine (n = 159). The primary end point was change from baseline HbA1c to 26 weeks (0.4% [4.4 mmol/mol] noninferiority margin). RESULTS: At 26 weeks, reduction in HbA1c was superior with BIL versus glargine (-0.82% [-8.9 mmol/mol] vs. -0.29% [-3.2 mmol/mol]; least squares mean difference -0.52%, 95% CI -0.67 to -0.38 [-5.7 mmol/mol, 95% CI -7.3 to -4.2; P < 0.001); greater reduction in HbA1c with BIL was maintained at 52 weeks. More BIL patients achieved HbA1c <7% (53 mmol/mol) at weeks 26 and 52 (P < 0.001). With BIL versus glargine, nocturnal hypoglycemia rate was 60% lower, more patients achieved HbA1c <7% (53 mmol/mol) without nocturnal hypoglycemia at 26 and 52 weeks (P < 0.001), and total hypoglycemia rates were lower at 52 weeks (P = 0.03). At weeks 26 and 52, glucose variability was lower (P < 0.01), basal insulin dose was higher (P < 0.001), and triglycerides and aminotransferases were higher with BIL versus glargine (P < 0.05). Liver fat content (LFC), assessed in a subset of patients (n = 162), increased from baseline with BIL versus glargine (P < 0.001), with stable levels between 26 and 52 weeks. CONCLUSIONS: BIL provided superior glycemic control versus glargine, with reduced nocturnal and total hypoglycemia, lower glucose variability, and increased triglycerides, aminotransferases, and LFC.
24
Effects of Intensive Glucose Lowering in Type 2 Diabetes
New England Journal of Medicine · 2008 · 7.9K citations · Full text
Medicine, Endocrinology, Physiology +14
Matthew C. Riddle, Julio Rosenstock, John Gerich · Diabetes Care · 2003 · 1.5K citations · Full text
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
Rury R. Holman, Melanie J. Davies, J Lévy et al. · New England Journal of Medicine · 2009 · 666 citations · Full text
Julio Rosenstock, Melanie J. Davies, Philip Home et al. · Diabetologia · 2008 · 447 citations · Full text